Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial

2021 ◽  
Author(s):  
Mads Ersbøll ◽  
Mikkel Jürgens ◽  
Philip Hasbak ◽  
Andreas Kjær ◽  
Emil Wolsk ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Cardiovascular Risk ◽  
Randomized Clinical Trial ◽  
Structure And Function ◽  
High Cardiovascular Risk ◽  
Myocardial Structure ◽  
And Function

Relationship Between Respiratory Function and Myocardial Structure and Function in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease

Kardiologiia ◽  
2015 ◽  
Vol 1_2015 ◽  
pp. 4-8
Author(s):  
E.D. Bazdyrev Bazdyrev ◽  
Yu.V. Bayrakova Bayrakova ◽  
O.M. Polikutina Polikutina ◽  
N.A. Bezdenezhnykh Bezdenezhnykh ◽  
Yu.S. Slepynina Slepynina ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Respiratory Function ◽  
Structure And Function ◽  
Myocardial Structure ◽  
And Function

scholarly journals A Low-Fat Vegan Diet Improves Glycemic Control and Cardiovascular Risk Factors in a Randomized Clinical Trial in Individuals With Type 2 Diabetes

Diabetes Care ◽  
2006 ◽  
Vol 29 (8) ◽  
pp. 1777-1783 ◽  
Author(s):  
N. D. Barnard ◽  
J. Cohen ◽  
D. J.A. Jenkins ◽  
G. Turner-McGrievy ◽  
L. Gloede ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Cardiovascular Risk ◽  
Glycemic Control ◽  
Cardiovascular Risk Factors ◽  
Randomized Clinical Trial ◽  
Vegan Diet ◽  
Low Fat

Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial

2011 ◽  
Vol 29 (1) ◽  
pp. 24-31 ◽  
Author(s):  
R. Fogari ◽  
A. Mugellini ◽  
M. Destro ◽  
L. Corradi ◽  
P. Lazzari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Structure And Function ◽  
Prospective Randomized Clinical Trial ◽  
Myocardial Structure ◽  
And Function

Lifestyle Intervention Using Mobile Technology in Patients with High Cardiovascular Risk: A Pragmatic Randomized Clinical Trial

2020 ◽  
Author(s):  
Ahmet İlker Tekkeşin ◽  
Mert İlker Hayıroğlu ◽  
Göksel Çinier ◽  
Yelda Soluk Özdemir ◽  
Duygu İnan ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cardiovascular Risk ◽  
Randomized Clinical Trial ◽  
Lifestyle Intervention ◽  
Mobile Technology ◽  
High Cardiovascular Risk

scholarly journals Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Basilio Pintaudi ◽  
Alessia Scatena ◽  
Gabriella Piscitelli ◽  
Vera Frison ◽  
Salvatore Corrao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Quality Of Care ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Cardiovascular Risk Factors ◽  
High Cardiovascular Risk ◽  
Very High

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, intensity/appropriateness of pharmacological treatment for diabetes and cardiovascular risk factors, presence of other complications and overall quality of care were evaluated. Results Overall, 473,740 subjects with type 2 diabetes (78.5% at very high cardiovascular risk, 20.9% at high risk and 0.6% at moderate risk) were evaluated. Among people with T2D at very high risk: 26.4% had retinopathy, 39.5% had albuminuria, 18.7% had a previous major cardiovascular event, 39.0% had organ damage, 89.1% had three or more risk factors. The use of DPP4-i markedly increased as cardiovascular risk increased. The prescription of secretagogues also increased and that of GLP1-RAs tended to increase. The use of SGLT2-i was still limited, and only slightly higher in subjects with very high cardiovascular risk. The overall quality of care, as summarized by the Q score, tended to be lower as the level of cardiovascular risk increased. Conclusions A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction. Several actions are necessary to improve the quality of care.

Sign in / Sign up

Export Citation Format

Share Document